P.A.W. Capital’s OptimizeRx OPRX Stock Holding History

P.A.W. Capital’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$915K	Buy	160,000 +70,000	+78%	+$402K	0.7%	49
2026 Q1	$565K	Buy	90,000 +35,000	+64%	+$325K	0.45%	54
2025 Q4	$674K	Buy	55,000 +5,000	+10%	+$81.7K	1.47%	19
2025 Q3	$1.02M	Hold	50,000	–	–	1.77%	17
2025 Q2	$675K	Buy	+50,000	New	+$547K	1.3%	18
2021 Q3	–	Sell	-35,000	Closed	-$2.17M	–	66
2021 Q2	$2.17M	Sell	35,000 -5,000	-13%	-$254K	1.82%	18
2021 Q1	$1.95M	Sell	40,000 -60,000	-60%	-$2.89M	1.72%	18
2020 Q4	$3.12M	Sell	100,000 -50,000	-33%	-$1.22M	2.75%	13
2020 Q3	$3.13M	Sell	150,000 -84,356	-36%	-$1.45M	3.4%	9
2020 Q2	$3.05M	Sell	234,356 -65,644	-22%	-$714K	3.45%	8
2020 Q1	$2.72M	Buy	300,000 +15,000	+5%	+$142K	3.66%	8
2019 Q4	$2.93M	Buy	285,000 +245,000	+613%	+$2.78M	3.12%	10
2019 Q3	$579K	Buy	+40,000	New	+$619K	0.72%	54

Other funds holding OPRX

WCA

Whetstone Capital Advisors Shawnee Mission, Kansas $380M AUM 20.01% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

P.A.W. Capital's OPRX Position: Q2 2026 in Review

P.A.W. Capital increased its OptimizeRx (OPRX) stake by 78% in Q2 2026, buying an estimated $402K and bringing the position to 160,000 shares worth $915K. The position accounts for 0.7% of the portfolio, ranked #49.

P.A.W. Capital first reported a position in OPRX in Q3 2019 and has held it in 13 quarters since. The position peaked at $3.13M in Q3 2020. 113 funds tracked by Wall St. Rank hold OPRX as of Q2 2026.

P.A.W. Capital held 160,000 shares of OptimizeRx worth $915K as of Q2 2026.
P.A.W. Capital bought 70,000 OptimizeRx shares in Q2 2026, an estimated $402K.
OptimizeRx made up 0.7% of P.A.W. Capital's portfolio in Q2 2026, its #49 holding.
P.A.W. Capital first reported a position in OptimizeRx in Q3 2019 and has held it in 13 quarters since.
P.A.W. Capital's OptimizeRx position peaked at $3.13M in Q3 2020.
113 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2026.

Based on P.A.W. Capital's 13F filing for Q2 2026, filed 28 Jul 2026.